Thomas Tray Sells 600 Shares of Incyte (NASDAQ:INCY) Stock

Incyte Corporation (NASDAQ:INCY) insider Thomas Tray sold 600 shares of the stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $98.25, for a total transaction of $58,950.00. Following the completion of the transaction, the insider directly owned 22,973 shares of the company’s stock, valued at approximately $2,257,097.25. The trade was a 2.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Thomas Tray also recently made the following trade(s):

• On Friday, December 19th, Thomas Tray sold 2,774 shares of Incyte stock. The stock was sold at an average price of $100.00, for a total value of $277,400.00.

Incyte Trading Up 0.2%

Shares of INCY stock opened at $100.91 on Wednesday. The company has a market cap of $19.81 billion, a PE ratio of 16.90, a price-to-earnings-growth ratio of 0.69 and a beta of 0.81. Incyte Corporation has a 1 year low of $53.56 and a 1 year high of $109.28. The stock’s 50 day simple moving average is $98.83 and its two-hundred day simple moving average is $85.31. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.20 and a quick ratio of 3.13.

Incyte (NASDAQ:INCY) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $2.26 earnings per share for the quarter, beating the consensus estimate of $1.65 by $0.61. Incyte had a return on equity of 26.56% and a net margin of 24.69%.The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.26 billion. During the same quarter in the previous year, the company posted $1.07 EPS. The company’s revenue for the quarter was up 20.0% compared to the same quarter last year. Research analysts predict that Incyte Corporation will post 4.86 earnings per share for the current year.

Incyte News Roundup

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Japan regulatory wins expand addressable market — Japan approved Zynyz® (retifanlimab) for first‑line advanced anal cancer and approved Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, supporting near‑term commercial upside in a major market. Japan approves Zynyz Japan approves Minjuvi combo
• Neutral Sentiment: Momentum/volume and analyst notes — A Zacks piece flagged a recent ~5.5% rally with above‑average volume but cautioned that upward earnings estimate revisions may be limited in the near term; this supports interest but doesn’t guarantee sustained upside. Zacks: INCY soars 5.5%
• Negative Sentiment: Insider selling could cap gains — Filings show Director/officer Thomas Tray sold 3,374 shares across Dec. 18–19 (including 600 shares on Dec. 18 at ~$98.25), and other insiders reported multi‑million dollar sales. Such concentrated insider disposals can create short‑term selling pressure or raise governance questions for some investors. SEC Form 4 InsiderTrades writeup

Analyst Ratings Changes

Several equities analysts recently commented on INCY shares. Barclays upped their price target on shares of Incyte from $101.00 to $115.00 and gave the company an “overweight” rating in a report on Monday, November 24th. Mizuho set a $121.00 target price on Incyte and gave the company an “outperform” rating in a research note on Monday, December 8th. Bank of America increased their price target on Incyte from $90.00 to $104.00 and gave the stock a “buy” rating in a report on Thursday, September 4th. Truist Financial restated a “hold” rating and set a $93.00 price objective (up previously from $79.00) on shares of Incyte in a report on Wednesday, October 29th. Finally, Zacks Research lowered Incyte from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. Eight investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $99.07.

Institutional Investors Weigh In On Incyte

A number of institutional investors and hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC increased its position in Incyte by 92.3% during the 1st quarter. AQR Capital Management LLC now owns 6,736,169 shares of the biopharmaceutical company’s stock valued at $405,787,000 after purchasing an additional 3,233,356 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in shares of Incyte by 701.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 2,730,648 shares of the biopharmaceutical company’s stock valued at $185,957,000 after purchasing an additional 2,390,084 shares in the last quarter. Norges Bank purchased a new position in Incyte during the second quarter valued at approximately $96,776,000. Pacer Advisors Inc. raised its stake in Incyte by 8,091.6% in the third quarter. Pacer Advisors Inc. now owns 1,248,642 shares of the biopharmaceutical company’s stock worth $105,897,000 after buying an additional 1,233,399 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in Incyte in the second quarter worth approximately $82,485,000. 96.97% of the stock is owned by institutional investors.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.